Idiopathic Pulmonary Fibrosis (IPF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036
Idiopathic
Pulmonary Fibrosis (IPF) Market Outlook
Thelansis’s “Idiopathic Pulmonary
Fibrosis (IPF) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2026 To 2036” covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Idiopathic
Pulmonary Fibrosis (IPF) treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
Idiopathic
Pulmonary Fibrosis (IPF) Overview
Idiopathic pulmonary fibrosis (IPF) is
a fatal fibrosing interstitial lung disease marked by aberrant epithelial
injury, fibroblast activation, and extracellular matrix deposition, yielding a
usual interstitial pneumonia pattern. Driven by genetic variants like MUC5B
polymorphisms, it causes structural destruction and respiratory failure.
Patients present with progressive exertional dyspnea, dry cough, and bibasal
velcro crackles. Diagnosis relies on high-resolution CT showing subpleural
honeycombing and traction bronchiectasis, alongside restrictive physiology on
function tests. For a decade, management relied solely on traditional
antifibrotics—nintedanib and pirfenidone—to slow decline. In 2026, the
therapeutic paradigm has fundamentally expanded. The oral preferential PDE4B
inhibitor nerandomilast is established as a landmark approved therapy, reducing
FVC decline as monotherapy or background combination care. Concurrently, data
from the Phase III TETON trials validate inhaled treprostinil to preserve lung
function and dramatically delay clinical worsening events. Lung transplantation
remains the definitive cure, requiring proactive symptom management and early
palliative integration.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by robust research, including:
- In-depth interviews with leading KOLs
and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based
automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets
and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the most
promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment